Conversion of a viral glycoprotein titer method from ELISA to BLI

Comparison of different methods of clarification of CHO cells

Application of Definitive Screening Design (DSD) to the icIEF Assay Development of Antibodies and Therapeutic Proteins

Strategies of CHO Cell Line Development and Toolbox Implementation for Improving Cell Line Productivity and Stability

Identification and Risk Mitigation of a Critical Process Parameter during Antibody Process Scale-up

Leveraging Innovation to Achieve Manufacturing Excellence Across Mammalian and Microbial Biologics Processes